Effective prevention of thrombocytopenia in mice using adenovirus-mediated transfer of HST-1 (FGF-4) gene. (original) (raw)

Amendment history:

Research Article Free access | 10.1172/JCI118099

T Ochiya, H Sakamoto, M Tsukamoto, I Saito, T Muto, T Sugimura, and M Terada

Genetics Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Konishi, H. in:JCI |PubMed |Google Scholar

Genetics Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Ochiya, T. in:JCI |PubMed |Google Scholar

Genetics Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Sakamoto, H. in:JCI |PubMed |Google Scholar

Genetics Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Tsukamoto, M. in:JCI |PubMed |Google Scholar

Genetics Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Saito, I. in:JCI |PubMed |Google Scholar

Genetics Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Muto, T. in:JCI |PubMed |Google Scholar

Genetics Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Sugimura, T. in:JCI |PubMed |Google Scholar

Genetics Division, National Cancer Center Research Institute, Tokyo, Japan.

Find articles by Terada, M. in:JCI |PubMed |Google Scholar

Published August 1, 1995 -More info

Published August 1, 1995 -Version history

View PDF

Abstract

HST-1 (FGF-4) gene product is a member of the fibroblast growth factor family with a signal peptide and plays a crucial role in limb development. We showed previously that an intraperitoneal injection of replication-deficient adenovirus containing the HST-1 gene (Adex1HST-1) into normal mice caused a twofold increase in peripheral platelet count. To investigate whether Adex1HST-1 could effectively prevent experimentally induced thrombocytopenia in mice, we injected Adex1HST-1 intraperitoneally into thrombocytopenic mice induced by administration of a chemotherapeutic agent and/or by irradiation. A single Adex1HST-1 injection caused continuously increased levels of serum HST-1 protein for at least 30 d and increased the count of large megakaryocytes in bone marrow, which specifically recovered platelet counts and more efficiently diminished the extent and duration of thrombocytopenia than any other reported cytokine or any combination of cytokines so far. In the other peripheral hematological parameters, no discernible differences were detected. No other apparent side effects were observed. Therefore, this method could be useful for treatment and/or prevention of thrombocytopenia induced by chemotherapy and/or irradiation for cancer treatment.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history